11 stories found
India's Sun Pharma is set to enter the "big leagues" of the pharmaceutical industry following a significant $12 billion deal in the United States. This acquisition or partnership is expected to substantially expand its market presence and influence.
Organon's shares jumped 15% after Sun Pharma reportedly agreed to an $11.8 billion buyout deal. The acquisition news significantly boosted Organon's stock performance.
Organon's stock saw an increase following reports that Sun Pharma is close to a $12 billion buyout agreement for the company.
Energy giant Shell has agreed to acquire Canadian shale producer ARC Resources in a deal valued between $13.6 billion and $22 billion, marking one of its largest acquisitions in a decade. The acquisition aims to expand Shell's presence in the Montney Basin.
Sun Pharma has obtained a bridge loan to finance its $12 billion acquisition of Organon.
Evercore ISI reports that talk of a potential deal between Sun Pharma and Organon & Co. (OGN) lacks confirmation and remains speculative.
The generic drugmakers, with many more expected to make announcements, are eyeing a share of the market for Semaglutide in India, which is estimated to be $1 billion over the next couple of years
India's Sun Pharma has announced its acquisition of the US-based pharmaceutical company Organon for approximately $12 billion. This deal represents one of the largest overseas pharma acquisitions for an Indian company.
Indian drugmaker Sun Pharmaceutical is set to acquire US-based Organon for $11.75 billion, a move expected to significantly expand Sun Pharma's global reach and US footprint.
Organon shares saw a jump in early trading after reports emerged of a potential bid from Sun Pharmaceutical.